Quadrant Capital Group’s ANI Pharmaceuticals ANIP Stock Holding History

Quadrant Capital Group’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$303K	Hold	3,662	–	–	0.01%	1079
2026 Q1	$282K	Hold	3,662	–	–	0.01%	1154
2025 Q4	$289K	Hold	3,662	–	–	0.01%	1171
2025 Q3	$335K	Hold	3,662	–	–	0.01%	1073
2025 Q2	$239K	Hold	3,662	–	–	0.01%	1232
2025 Q1	$245K	Buy	3,662 +3,650	+30,417%	+$218K	0.01%	1193
2024 Q4	$664	Hold	12	–	–	﹤0.01%	2625
2024 Q3	$716	Hold	12	–	–	﹤0.01%	2629
2024 Q2	$765	Hold	12	–	–	﹤0.01%	2588
2024 Q1	$830	Hold	12	–	–	﹤0.01%	2607
2023 Q4	$662	Hold	12	–	–	﹤0.01%	2596
2023 Q3	$697	Hold	12	–	–	﹤0.01%	2528
2023 Q2	$646	Hold	12	–	–	﹤0.01%	2543
2023 Q1	$477	Sell	12 -12	-50%	-$506	﹤0.01%	2611
2022 Q4	$966	Sell	24 -6	-20%	-$225	﹤0.01%	2554
2022 Q3	$1K	Sell	30 -13	-30%	-$445	﹤0.01%	2464
2022 Q2	$1K	Buy	43 +14	+48%	+$404	﹤0.01%	2316
2022 Q1	$1K	Sell	29 -22	-43%	-$820	﹤0.01%	2239
2021 Q4	$2K	Buy	51 +25	+96%	+$1.07K	﹤0.01%	2100
2021 Q3	$1K	Buy	+26	New	+$808	﹤0.01%	2236

Other funds holding ANIP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

GACM

Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Quadrant Capital Group's ANIP Position: Q2 2026 in Review

Quadrant Capital Group held its ANI Pharmaceuticals (ANIP) position steady in Q2 2026 at 3,662 shares worth $303K. The position accounts for 0.01% of the portfolio, ranked #1079.

Quadrant Capital Group first reported a position in ANIP in Q3 2021 and has held it in 20 quarters since. The position peaked at $335K in Q3 2025. 307 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

Quadrant Capital Group held 3,662 shares of ANI Pharmaceuticals worth $303K as of Q2 2026.
Quadrant Capital Group left its ANI Pharmaceuticals share count unchanged in Q2 2026.
ANI Pharmaceuticals made up 0.01% of Quadrant Capital Group's portfolio in Q2 2026, its #1079 holding.
Quadrant Capital Group first reported a position in ANI Pharmaceuticals in Q3 2021 and has held it in 20 quarters since.
Quadrant Capital Group's ANI Pharmaceuticals position peaked at $335K in Q3 2025.
307 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.